2 completed, 2 recruiting, 2 terminated, 1 withdrawn. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 2, Recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Acute Chest Syndrome: new trials by email Literature Review of Acute Chest Syndrome trials Research Report on Acute Chest Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease Lidocain, Placebo, Standard of care - Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Recruiting | Nantes University Hospital | 104 | 2026-07-03 | 2026-09-09 |
| Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease Tocilizumab (RoActemra®, 20 mg/mL)., Placebo (NaCl 0.9%) - Sickle Cell Disease, Acute Chest Syndrome | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 130 | 2025-08-27 | 2026-06-24 |
| Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease. Brilinta, Placebo - Sickle Cell Disease | Phase 3 | Withdrawn | AstraZeneca | 2020-06-30 | 2020-07-15 | |
| Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin Aspirin, Atorvastatin, Placebo Aspirin - Acute Chest Syndrome | Phase 3 | Terminated | Dr. med. Mahir Karakas | 68 | 2020-02-21 | 2022-05-24 |
| Therapeutic Anticoagulation Strategy for Acute Chest Syndrome Prophylactic anticoagulation ( INNOHEP®), Curative anticoagulation ( INNOHEP®) - Anemia, Sickle Cell | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 198 | 2016-12-16 | 2024-02-09 |
| Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study) Nitric Oxide, Placebo - Sickle Cell Disease, Acute Chest Syndrome | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 100 | 2008-12-01 | 2013-08-02 |
| Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease Dexamethasone, Placebo - Anemia, Sickle Cell | Phase 3 | Terminated | Children's Hospital Medical Center, Cincinnati | 12 | 2006-12-01 | 2013-04-09 |
Anemia, Sickle Cell (6) · Vaso-Occlusive Crises (2) · Acute Lung Injury (1) · Agnosia (1) · Anemia (1) · Rare Diseases (1)
Anemia, Hemolytic (7) · Anemia, Hemolytic, Congenital (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Hemoglobinopathies (7) · Lung Diseases (7) · Respiration Disorders (7) · Respiratory Tract Diseases (7) · Anemia (6) · Pathological Conditions, Signs and Symptoms (2) · Anemia, Sickle Cell (1) · Disease Attributes (1) · Lung Injury (1)
Aspirin (1) · Atorvastatin (1) · Dexamethasone (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Nitric Oxide (1) · Sodium Chloride (1) · Standard of Care (1) · Ticagrelor (1) · Tinzaparin (1) · tocilizumab (1)
Assistance Publique - Hôpitaux de Paris (3) · AstraZeneca (1) · Children's Hospital Medical Center, Cincinnati (1) · Dr. med. Mahir Karakas (1) · Nantes University Hospital (1)
France (4) · Germany (1) · Guadeloupe (1) · United States (1)
Anders Berggren, MD, PhD (1) · Armand Mekontso Dessap, MD, PhD (1) · Bernard Maitre, MD, PhD (1) · Charles Quinn, MD (1) · Mahir Karakas, MD (1)
PMID 21848879, PMID 26431718, PMID 40209087
2023 (1), U54HL070587 (1)